{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:41Z","timestamp":1787797121071,"version":"build-2784847793"},"publisher-location":"Cham","reference-count":101,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030426668","type":"print"},{"value":"9783030426675","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-42667-5_8","type":"book-chapter","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T17:03:31Z","timestamp":1587143011000},"page":"175-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Francesca L.","family":"Guest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Rahmoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"8_CR1","unstructured":"World Alzheimer Report 2016, Improving healthcare for people living with dementia. \nhttps:\/\/www.alz.co.uk\/research\/worldalzheimerreport2016sheet.pdf"},{"key":"8_CR2","unstructured":"World Population Forecast (2020\u20132050). \nhttps:\/\/www.worldometers.info\/world-population\/#table-forecast"},{"issue":"1","key":"8_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"E Nichols","year":"2019","unstructured":"GBD 2016 Dementia Collaborators, Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F et al (2019) Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(1):88\u2013106","journal-title":"Lancet Neurol"},{"issue":"2","key":"8_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR et al (2019) Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis 70(2):323\u2013341","journal-title":"J Alzheimers Dis"},{"key":"8_CR5","unstructured":"Perneczky R (ed) Biomarkers for preclinical Alzheimer\u2019s disease (Neuromethods), 1st edn. Humana Press; Totowa, NJ, USA. 2018 edition (3 April 2018). ISBN-10: 1493976737"},{"issue":"3","key":"8_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885\u2013890","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"8_CR7","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83(13):4913\u20134917","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"8_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0896-6273(02)00830-9","volume":"35","author":"N Burgess","year":"2002","unstructured":"Burgess N, Maguire EA, O\u2019Keefe J (2002) The human hippocampus and spatial and episodic memory. Neuron 35(4):625\u2013641","journal-title":"Neuron"},{"issue":"2","key":"8_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0166-4328(99)00044-3","volume":"103","author":"H Eichenbaum","year":"1999","unstructured":"Eichenbaum H (1999) The hippocampus and mechanisms of declarative memory. Behav Brain Res 103(2):123\u2013133","journal-title":"Behav Brain Res"},{"issue":"7","key":"8_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7326\/0003-4819-140-7-200404060-00008","volume":"140","author":"EB Larson","year":"2004","unstructured":"Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L et al (2004) Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 140(7):501\u2013509","journal-title":"Ann Intern Med"},{"issue":"3","key":"8_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3233\/JAD-170698","volume":"62","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Minguillon C, Rami L, Gispert JD (2018) The rationale behind the new Alzheimer\u2019s disease conceptualization: lessons learned during the last decades. J Alzheimers Dis 62(3):1067\u20131077","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"8_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/fn.2019.85929","volume":"57","author":"RA Armstrong","year":"2019","unstructured":"Armstrong RA (2019) Risk factors for Alzheimer\u2019s disease. Folia Neuropathol 57(2):87\u2013105","journal-title":"Folia Neuropathol"},{"issue":"3","key":"8_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194735","volume":"13","author":"E Ford","year":"2018","unstructured":"Ford E, Greenslade N, Paudyal P, Bremner S, Smith HE, Banerjee S et al (2018) Predicting dementia from primary care records: a systematic review and meta-analysis. PLoS One 13(3):e0194735. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0194735","journal-title":"PLoS One"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-030-05542-4_15","volume":"1118","author":"FL Guest","year":"2019","unstructured":"Guest FL (2019) Early detection and treatment of patients with Alzheimer\u2019s disease: future perspectives. Adv Exp Med Biol 1118:295\u2013317","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"8_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","volume":"67","author":"JL Cummings","year":"2019","unstructured":"Cummings JL, Tong G, Ballard C (2019) Treatment combinations for Alzheimer\u2019s disease: current and future pharmacotherapy options. J Alzheimers Dis 67(3):779\u2013794","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"8_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2165\/00023210-200216120-00003","volume":"16","author":"PM Doraiswamy","year":"2002","unstructured":"Doraiswamy PM (2002) Non-cholinergic strategies for treating and preventing Alzheimer\u2019s disease. CNS Drugs 16(12):811\u2013824","journal-title":"CNS Drugs"},{"issue":"6","key":"8_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40266-015-0266-9","volume":"32","author":"JS Buckley","year":"2015","unstructured":"Buckley JS, Salpeter SR (2015) A risk-benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging 32(6):453\u2013467","journal-title":"Drugs Aging"},{"key":"8_CR18","doi-asserted-by":"publisher","unstructured":"Tolar M, Abushakra S, Sabbagh M (2019) The path forward in Alzheimer\u2019s disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement.. pii: S1552-5260(19)35450-0. \nhttps:\/\/doi.org\/10.1016\/j.jalz.2019.09.075","DOI":"10.1016\/j.jalz.2019.09.075"},{"issue":"6","key":"8_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.18773\/austprescr.2015.071","volume":"38","author":"D Kitching","year":"2015","unstructured":"Kitching D (2015) Depression in dementia. Aust Prescr 38(6):209\u2013211","journal-title":"Aust Prescr"},{"issue":"6","key":"8_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jalz.2015.05.016","volume":"11","author":"M Baumgart","year":"2015","unstructured":"Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11(6):718\u2013726","journal-title":"Alzheimers Dement"},{"issue":"4","key":"8_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","volume":"88","author":"C Reitz","year":"2014","unstructured":"Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88(4):640\u2013651","journal-title":"Biochem Pharmacol"},{"issue":"3 Suppl","key":"8_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/JAD-2006-9S338","volume":"9","author":"A Goate","year":"2006","unstructured":"Goate A (2006) Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer\u2019s disease. J Alzheimers Dis 9(3 Suppl):341\u2013347","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"8_CR23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm1096-1146","volume":"2","author":"CA Lemere","year":"1996","unstructured":"Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC et al (1996) The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2(10):1146\u20131150","journal-title":"Nat Med"},{"issue":"6543","key":"8_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"EI Rogaev","year":"1995","unstructured":"Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y et al (1995) Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature 376(6543):775\u2013778","journal-title":"Nature"},{"issue":"8","key":"8_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2(8):864\u2013870","journal-title":"Nat Med"},{"issue":"5123","key":"8_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261(5123):921\u2013923","journal-title":"Science"},{"issue":"16","key":"8_CR27","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16):1349\u20131356","journal-title":"JAMA"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/CIA.S105769","volume":"11","author":"M Giri","year":"2016","unstructured":"Giri M, Zhang M, Lu Y (2016) Genes associated with Alzheimer\u2019s disease: an overview and current status. Clin Interv Aging 11:665\u2013681","journal-title":"Clin Interv Aging"},{"issue":"2","key":"8_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-016-0011-3","volume":"32","author":"L Shen","year":"2016","unstructured":"Shen L, Jia J (2016) An overview of genome-wide association studies in Alzheimer\u2019s disease. Neurosci Bull 32(2):183\u2013190","journal-title":"Neurosci Bull"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-94-007-5416-4_14","volume":"5","author":"VJ De-Paula","year":"2012","unstructured":"De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer\u2019s disease. Subcell Biochem 5:329\u2013352","journal-title":"Subcell Biochem"},{"issue":"1\u20133","key":"8_CR31","first-page":"81","volume":"22","author":"JT Huse","year":"1991","unstructured":"Huse JT, Doms RW (1991) Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer\u2019s disease. Mol Neurobiol 22(1\u20133):81\u201398","journal-title":"Mol Neurobiol"},{"issue":"4","key":"8_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259","journal-title":"Acta Neuropathol"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"F Kametani","year":"2018","unstructured":"Kametani F, Hasegawa M (2018) Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front Neurosci 12:25. \nhttps:\/\/doi.org\/10.3389\/fnins.2018.00025","journal-title":"Front Neurosci"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fnins.2019.00529","volume":"13","author":"K Zhu","year":"2019","unstructured":"Zhu K, Wang X, Sun B, Wu J, Lu H, Zhang X et al (2019) Primary age-related tauopathy in human subcortical nuclei. Front Neurosci 13:529. \nhttps:\/\/doi.org\/10.3389\/fnins.2019.00529","journal-title":"Front Neurosci"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0074-7742(07)82012-5","volume":"82","author":"J Rogers","year":"2007","unstructured":"Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer\u2019s disease and Parkinson\u2019s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235\u2013246","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"8_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1471-4159.2009.06511.x","volume":"112","author":"MA Meraz-R\u00edos","year":"2010","unstructured":"Meraz-R\u00edos MA, Lira-De Le\u00f3n KI, Campos-Pe\u00f1a V, De Anda-Hern\u00e1ndez MA, Mena-L\u00f3pez R (2010) Tau oligomers and aggregation in Alzheimer\u2019s disease. J Neurochem 112(6):1353\u20131367","journal-title":"J Neurochem"},{"issue":"2","key":"8_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bpa.12478","volume":"27","author":"CS White","year":"2017","unstructured":"White CS, Lawrence CB, Brough D, Rivers-Auty J (2017) Inflammasomes as therapeutic targets for Alzheimer\u2019s disease. Brain Pathol 27(2):223\u2013234","journal-title":"Brain Pathol"},{"issue":"7685","key":"8_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D et al (2017) Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature 552(7685):355\u2013361","journal-title":"Nature"},{"issue":"5","key":"8_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-013-1139-0","volume":"126","author":"H Braak","year":"2013","unstructured":"Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-\u03b2 changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126(5):631\u2013641","journal-title":"Acta Neuropathol"},{"issue":"Pt 9","key":"8_CR40","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1093\/brain\/awu176","volume":"137","author":"AL Young","year":"2014","unstructured":"Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S et al (2014) A data-driven model of biomarker changes in sporadic Alzheimer\u2019s disease. Brain 137(Pt 9):2564\u20132577","journal-title":"Brain"},{"issue":"16","key":"8_CR41","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1212\/WNL.0000000000002593","volume":"86","author":"C Xiong","year":"2016","unstructured":"Xiong C, Jasielec MS, Weng H, Fagan AM, Benzinger TL, Head D et al (2016) Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology 86(16):1499\u20131506","journal-title":"Neurology"},{"issue":"7","key":"8_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/dneu.22715","volume":"79","author":"F Alhajraf","year":"2019","unstructured":"Alhajraf F, Ness D, Hye A, Strydom A (2019) Plasma amyloid and tau as dementia biomarkers in Down syndrome: systematic review and meta-analyses. Dev Neurobiol 79(7):684\u2013698","journal-title":"Dev Neurobiol"},{"issue":"3","key":"8_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamaneurol.2014.3314","volume":"72","author":"AS Fleisher","year":"2015","unstructured":"Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM et al (2015) Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 72(3):316\u2013324","journal-title":"JAMA Neurol"},{"issue":"3","key":"8_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","volume":"15","author":"IT Lott","year":"2019","unstructured":"Lott IT, Head E (2019) Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol 15(3):135\u2013147","journal-title":"Nat Rev Neurol"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.freeradbiomed.2017.08.009","volume":"114","author":"F Domenico Di","year":"2018","unstructured":"Di Domenico F, Tramutola A, Foppoli C, Head E, Perluigi M, Butterfield DA (2018) mTOR in Down syndrome: role in A\u00df and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radic Biol Med 114:94\u2013101","journal-title":"Free Radic Biol Med"},{"key":"8_CR46","doi-asserted-by":"crossref","unstructured":"Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Alzheimer\u2019s Prevention Initiative (2018) The Alzheimer\u2019s Prevention Initiative Autosomal-Dominant Alzheimer\u2019s Disease Trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer\u2019s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y) 4:150\u2013160","DOI":"10.1016\/j.trci.2018.02.002"},{"issue":"28","key":"8_CR47","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K et al (2012) An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique a\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J Neurosci 32(28):9677\u20139689","journal-title":"J Neurosci"},{"issue":"8","key":"8_CR48","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.mayocp.2017.04.016","volume":"92","author":"K Josephs","year":"2017","unstructured":"Josephs K (2017) Current understanding of neurodegenerative diseases associated with the protein tau. Mayo Clin Proc 92(8):1291\u20131303","journal-title":"Mayo Clin Proc"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","volume":"1118","author":"J Cummings","year":"2019","unstructured":"Cummings J (2019) The role of biomarkers in Alzheimer\u2019s disease drug development. Adv Exp Med Biol 1118:29\u201361","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"8_CR50","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cns.12983","volume":"24","author":"J Feng","year":"2018","unstructured":"Feng J, Wang JX, Du YH, Liu Y, Zhang W, Chen JF et al (2018) Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP\/PS1 transgenic mice. CNS Neurosci Ther 24(12):1207\u20131218","journal-title":"CNS Neurosci Ther"},{"key":"8_CR51","doi-asserted-by":"crossref","unstructured":"M\u00fcnch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ et al (1998) Alzheimer\u2019s disease \u2013 synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439\u2013461","DOI":"10.1007\/s007020050069"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0006-8993(01)02872-4","volume":"920","author":"A Wong","year":"2001","unstructured":"Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T et al (2001) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer\u2019s disease. Brain Res 920:32\u201340","journal-title":"Brain Res"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuint.2015.10.011","volume":"95","author":"M Venigalla","year":"2016","unstructured":"Venigalla M, Sonego S, Gyengesi E, Sharman MJ, M\u00fcnch G (2016) Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer\u2019s disease. Neurochem Int 95:63\u201374","journal-title":"Neurochem Int"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/nyas.12987","volume":"1363","author":"ME Figueiredo-Pereira","year":"2016","unstructured":"Figueiredo-Pereira ME, Corwin C, Babich J (2016) Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. Ann N Y Acad Sci 1363:125\u2013137","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"8_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1590\/1980-57642015DN92000015","volume":"9","author":"CHF Camargo","year":"2015","unstructured":"Camargo CHF, Justus FF, Retzlaff G, Blood MRY, Schafranski MD (2015) Action of anti-TNF-\u03b1 drugs on the progression of Alzheimer\u2019s disease: a case report. Dement Neuropsychol 9(2):196\u2013200","journal-title":"Dement Neuropsychol"},{"issue":"21","key":"8_CR56","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","volume":"84","author":"J Butchart","year":"2015","unstructured":"Butchart J, Brook L, Hopkins V, Teeling J, P\u00fcntener U, Culliford D et al (2015) Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 84(21):2161\u20132168","journal-title":"Neurology"},{"key":"8_CR57","doi-asserted-by":"publisher","unstructured":"Mazzanti G, Di Giacomo S (2016) Curcumin and resveratrol in the management of cognitive disorders: what is the clinical evidence? Molecules 21(9). pii: E1243. \nhttps:\/\/doi.org\/10.3390\/molecules21091243","DOI":"10.3390\/molecules21091243"},{"issue":"1\u20132","key":"8_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ijpharm.2017.05.015","volume":"526","author":"R Barbara","year":"2017","unstructured":"Barbara R, Belletti D, Pederzoli F, Masoni M, Keller J, Ballestrazzi A et al (2017) Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. Int J Pharm 526(1\u20132):413\u2013424","journal-title":"Int J Pharm"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"146476","DOI":"10.1016\/j.brainres.2019.146476","volume":"1725","author":"SD Voulgaropoulou","year":"2019","unstructured":"Voulgaropoulou SD, van Amelsvoort TAMJ, Prickaerts J, Vingerhoets C (2019) The effect of curcumin on cognition in Alzheimer\u2019s disease and healthy aging: a systematic review of pre-clinical and clinical studies. Brain Res 1725:146476. \nhttps:\/\/doi.org\/10.1016\/j.brainres.2019.146476","journal-title":"Brain Res"},{"issue":"7","key":"8_CR60","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"3","key":"8_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):263\u2013269","journal-title":"Alzheimers Dement"},{"issue":"15","key":"8_CR62","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","volume":"86","author":"SM Landau","year":"2016","unstructured":"Landau SM, Horng A, Fero A, Jagust WJ (2016) Alzheimer\u2019s Disease Neuroimaging Initiative. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology 86(15):1377\u20131385","journal-title":"Neurology"},{"issue":"1","key":"8_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","volume":"30","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D et al (2016) Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord 30(1):1\u20137","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"8_CR64","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2174\/1567205014666161213120807","volume":"14","author":"S Ellendt","year":"2017","unstructured":"Ellendt S, Vobeta B, Kohn N, Wagels L, Goerlich KS, Drexler E et al (2017) Predicting stability of mild cognitive impairment (MCI): findings of a community based sample. Curr Alzheimer Res 14(6):608\u2013619","journal-title":"Curr Alzheimer Res"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3233\/JAD-150900","volume":"52","author":"KJ Bangen","year":"2016","unstructured":"Bangen KJ, Clark AL, Werhane M, Edmonds EC, Nation DA, Evangelista N et al (2016) Cortical amyloid burden differences across empirically-derived mild cognitive impairment subtypes and interaction with APOE varepsilon4 genotype. J Alzheimers Dis 52:849\u2013861","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"8_CR66","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/archneur.63.5.674","volume":"63","author":"GA Jicha","year":"2006","unstructured":"Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ et al (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63(5):674\u2013681","journal-title":"Arch Neurol"},{"issue":"19","key":"8_CR67","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19):1924\u20131938","journal-title":"JAMA"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228\u2013234","journal-title":"Lancet Neurol"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L et al (2007) Prediction of Alzheimer\u2019s disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23:316\u2013320","journal-title":"Dement Geriatr Cogn Disord"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H et al (2007) Amyloid beta peptide ratio 42\/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 101:1053\u20131059","journal-title":"J Neurochem"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P et al (2017) Cerebrospinal fluid Abeta42\/40 corresponds better than Abeta42 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis 55:813\u2013822","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"8_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-015-0114-5","volume":"7","author":"J Dumurgier","year":"2015","unstructured":"Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL et al (2015) Cerebrospinal fluid amyloid-\u03b2 42\/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther 7(1):30. \nhttps:\/\/doi.org\/10.1186\/s13195-015-0114-5","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"8_CR73","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jamda.2016.02.015","volume":"17","author":"EE Roeck De","year":"2016","unstructured":"De Roeck EE, Engelborghs S, Dierckx E (2016) Next generation brain health depends on early Alzheimer disease diagnosis: from a timely diagnosis to future population screening. J Am Med Dir Assoc 17(5):452\u2013453","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"8_CR74","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3233\/JAD-2011-110566","volume":"27","author":"M Bjerke","year":"2011","unstructured":"Bjerke M, Zetterberg H, Edman \u00c5, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer\u2019s disease. J Alzheimers Dis 27(3):665\u2013676","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"8_CR75","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JAD-130107","volume":"36","author":"S Slaets","year":"2013","unstructured":"Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP et al (2013) Cerebrospinal fluid A\u03b21-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36(4):759\u2013767","journal-title":"J Alzheimers Dis"},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.03.003","volume":"138\u2013140","author":"F Llorens","year":"2016","unstructured":"Llorens F, Schmitz M, Ferrer I, Zerr I (2016) CSF biomarkers in neurodegenerative and vascular dementias. Prog Neurobiol 138\u2013140:36\u201353","journal-title":"Prog Neurobiol"},{"issue":"3","key":"8_CR77","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3233\/JAD-170773","volume":"62","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) The past and the future of Alzheimer\u2019s disease fluid biomarkers. J Alzheimers Dis 62(3):1125\u20131140","journal-title":"J Alzheimers Dis"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","volume":"1180","author":"HD Soares","year":"2009","unstructured":"Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M (2009) Identifying early markers of Alzheimer\u2019s disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180:56\u201367","journal-title":"Ann N Y Acad Sci"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/978-1-4939-2627-5_32","volume":"1303","author":"R Perneczky","year":"2016","unstructured":"Perneczky R, Guo LH (2016) Plasma proteomics biomarkers in Alzheimer\u2019s disease: latest advances and challenges. Methods Mol Biol 1303:521\u2013529","journal-title":"Methods Mol Biol"},{"issue":"5","key":"8_CR80","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00221-018-5210-x","volume":"236","author":"J Vogelgsang","year":"2018","unstructured":"Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J (2018) Multiplex immunoassay measurement of amyloid-\u03b242 to amyloid-\u03b240 ratio in plasma discriminates between dementia due to Alzheimer\u2019s disease and dementia not due to Alzheimer\u2019s disease. Exp Brain Res 236(5):1241\u20131250","journal-title":"Exp Brain Res"},{"issue":"8","key":"8_CR81","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuint.2009.08.006","volume":"55","author":"N Bastard Le","year":"2009","unstructured":"Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S (2009) No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 55(8):820\u2013825","journal-title":"Neurochem Int"},{"key":"8_CR82","doi-asserted-by":"publisher","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ et al (2018) Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. pii: S1552-5260(18)30067-0. \nhttps:\/\/doi.org\/10.1016\/j.jalz.2018.02.013","DOI":"10.1016\/j.jalz.2018.02.013"},{"issue":"4","key":"8_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194802","volume":"13","author":"JS Neergaard","year":"2018","unstructured":"Neergaard JS, Dragsb\u00e6k K, Christiansen C, Karsdal MA, Brix S, Henriksen K (2018) Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: a prospective study. PLoS One 13(4):e0194802. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0194802","journal-title":"PLoS One"},{"issue":"3","key":"8_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.936","volume":"8","author":"S Ouma","year":"2018","unstructured":"Ouma S, Suenaga M, B\u00f6l\u00fckba\u015f\u0131 Hatip FF, Hatip-Al-Khatib I, Tsuboi Y et al (2018) Serum vitamin D in patients with mild cognitive impairment and Alzheimer\u2019s disease. Brain Behav 8(3):e00936. \nhttps:\/\/doi.org\/10.1002\/brb3.936","journal-title":"Brain Behav"},{"issue":"1","key":"8_CR85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13195-017-0291-5","volume":"9","author":"HJ Choi","year":"2017","unstructured":"Choi HJ, Byun MS, Yi D, Sohn BK, Lee JH, Lee JY et al (2017) Associations of thyroid hormone serum levels with in-vivo Alzheimer\u2019s disease pathologies. Alzheimers Res Ther 9(1):64. \nhttps:\/\/doi.org\/10.1186\/s13195-017-0291-5","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"8_CR86","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3233\/JAD-170721","volume":"61","author":"X Cao","year":"2018","unstructured":"Cao X, Zhu M, He Y, Chu W, Du Y, Du H (2018) Increased serum acylated ghrelin levels in patients with mild cognitive impairment. J Alzheimers Dis 61(2):545\u2013552","journal-title":"J Alzheimers Dis"},{"key":"8_CR87","doi-asserted-by":"crossref","unstructured":"Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM et al (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med 15(1):e1002482. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.1002482","DOI":"10.1371\/journal.pmed.1002482"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuroscience.2018.03.016","volume":"379","author":"H Wei","year":"2018","unstructured":"Wei H, Xu Y, Xu W, Zhou Q, Chen Q, Yang M et al (2018) Serum Exosomal miR-223 serves as a potential diagnostic and prognostic biomarker for dementia. Neuroscience 379:167\u2013176","journal-title":"Neuroscience"},{"issue":"2","key":"8_CR89","first-page":"87","volume":"31","author":"TT Yang","year":"2018","unstructured":"Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC (2018) The serum exosome derived MicroRNA-135a, \u2212193b, and \u2212384 were potential Alzheimer\u2019s disease biomarkers. Biomed Environ Sci 31(2):87\u201389","journal-title":"Biomed Environ Sci"},{"issue":"2","key":"8_CR90","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1620\/tjem.242.129","volume":"242","author":"Y Wu","year":"2017","unstructured":"Wu Y, Xu J, Xu J, Cheng J, Jiao D, Zhou C et al (2017) Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer\u2019s disease. Tohoku J Exp Med 242(2):129\u2013136","journal-title":"Tohoku J Exp Med"},{"key":"8_CR91","doi-asserted-by":"publisher","unstructured":"Magalh\u00e3es TNC, Weiler M, Teixeira CVL, Hayata T, Moraes AS, Boldrini VO et al (2017) Systemic inflammation and multimodal biomarkers in amnestic mild cognitive impairment and Alzheimer\u2019s disease. Mol Neurobiol. \nhttps:\/\/doi.org\/10.1007\/s12035-017-0795-9","DOI":"10.1007\/s12035-017-0795-9"},{"issue":"10","key":"8_CR92","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jnnp-2017-316201","volume":"88","author":"KSP Lai","year":"2017","unstructured":"Lai KSP, Liu CS, Rau A, Lanct\u00f4t KL, K\u00f6hler CA, Pakosh M et al (2017) Peripheral inflammatory markers in Alzheimer\u2019s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry 88(10):876\u2013882","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neurobiolaging.2015.10.021","volume":"38","author":"A Chen","year":"2016","unstructured":"Chen A, Oakley AE, Monteiro M, Tuomela K, Allan LM, Mukaetova-Ladinska EB et al (2016) Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging 38:56\u201367","journal-title":"Neurobiol Aging"},{"key":"8_CR94","doi-asserted-by":"publisher","unstructured":"Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C et al (2019) Tau PET imaging with 18F-PI-2620 in patients with Alzheimer\u2019s disease and healthy controls: a first-in-human study. J Nucl Med. \nhttps:\/\/doi.org\/10.2967\/jnumed.119.236224\n\n. pii: jnumed.119.236224. [Epub ahead of print]","DOI":"10.2967\/jnumed.119.236224"},{"issue":"10","key":"8_CR95","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A et al (2019) Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur J Nucl Med Mol Imaging 46(10):2178\u20132189","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8_CR96","doi-asserted-by":"publisher","unstructured":"Bullich S, Barret O, Constantinescu C, Sandiego C, Mueller A, Berndt M et al (2019) Evaluation of dosimetry, quantitative methods and test-retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain. J Nucl Med. \nhttps:\/\/doi.org\/10.2967\/jnumed.119.236240\n\n. pii: jnumed.119.236240. [Epub ahead of print]","DOI":"10.2967\/jnumed.119.236240"},{"key":"8_CR97","doi-asserted-by":"publisher","first-page":"e0134750","DOI":"10.1371\/journal.pone.0134750","volume":"10","author":"G Coppola","year":"2015","unstructured":"Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G et al (2015) Optical coherence tomography in Alzheimer\u2019s disease: a meta-analysis. PLoS One 10:e0134750. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0134750","journal-title":"PLoS One"},{"key":"8_CR98","doi-asserted-by":"publisher","unstructured":"Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ et al (2017) Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight 2(16). \nhttps:\/\/doi.org\/10.1172\/jci.insight.93621\n\n. pii: 93621. [Epub ahead of print]","DOI":"10.1172\/jci.insight.93621"},{"issue":"11","key":"8_CR99","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3928\/23258160-20191031-06","volume":"50","author":"SP Yoon","year":"2019","unstructured":"Yoon SP, Thompson AC, Polascik BW, Calixte C, Burke JR, Petrella JR et al (2019) Correlation of OCTA and volumetric MRI in mild cognitive impairment and Alzheimer\u2019s disease. Ophthalmic Surg Lasers Imaging Retina 50(11):709\u2013718","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"11","key":"8_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224180","volume":"14","author":"JI Kim","year":"2019","unstructured":"Kim JI, Kang BH (2019) Decreased retinal thickness in patients with Alzheimer\u2019s disease is correlated with disease severity. PLoS One 14(11):e0224180. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0224180","journal-title":"PLoS One"},{"key":"8_CR101","doi-asserted-by":"publisher","unstructured":"Medina M (2018) An overview on the clinical development of tau-based therapeutics. Int J Mol Sci 19(4). pii: E1160. \nhttps:\/\/doi.org\/10.3390\/ijms19041160","DOI":"10.3390\/ijms19041160"}],"container-title":["Advances in Experimental Medicine and Biology","Reviews on New Drug Targets in Age-Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-42667-5_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T17:22:20Z","timestamp":1587144140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-42667-5_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030426668","9783030426675"],"references-count":101,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-42667-5_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"18 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}